Robert Lorne Hopfner insider trades: Evommune (EVMN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | EVMN | ↑ Buy | 1,000 | $17.35 | $17K | By Trust | Dec 22, 2025 (3d) |
| Aug 1, 2023 | INZY | ↑ Buy | 833,333 | $4.80 | $4.0M | By Pivotal | Aug 3, 2023 (2d) |
| May 12, 2023 | INZY | ↑ Buy | 447,932 | $6.36 | $2.8M | By Pivotal | May 15, 2023 (3d) |
| Mar 29, 2023 | INZY | ↑ Buy | 344,592 | $4.54 | $1.6M | Indirect | Mar 30, 2023 (1d) |
| Mar 28, 2023 | INZY | ↑ Buy | 207,840 | $4.05 | $841K | Indirect | Mar 29, 2023 (1d) |
| Apr 19, 2022 | INZY | ↑ Buy | 1,070,000 | $3.69 | $3.9M | By Pivotal bioVenture Partners Fund I, L | Apr 20, 2022 (1d) |
| Aug 2, 2021 | RLYB | ↑ Buy | 576,923 | $13.00 | $7.5M | Pivotal bioVenture Partners Fund I L.P | Aug 4, 2021 (2d) |
| Feb 10, 2021 | PCVX | ↓ Sell | 378,698 | $27.34 | $10.4M | By Pivotal bioVenture Partners Fund I, L | Feb 10, 2021 (0d) |
| Feb 3, 2021 | PCVX | ↓ Sell | 17,002 | $25.12 | $427K | By Pivotal bioVenture Partners Fund I, L | Feb 4, 2021 (1d) |
| Jan 28, 2021 | PCVX | ↓ Sell | 2,000 | $25.07 | $50K | By Pivotal bioVenture Partners Fund I, L | Feb 2, 2021 (5d) |
| Jan 27, 2021 | PCVX | ↓ Sell | 55,254 | $25.62 | $1.4M | By Pivotal bioVenture Partners Fund I, L | Jan 27, 2021 (0d) |
| Jan 22, 2021 | PCVX | ↓ Sell | 30,529 | $25.28 | $772K | By Pivotal bioVenture Partners Fund I, L | Jan 22, 2021 (0d) |
| Jan 19, 2021 | PCVX | ↓ Sell | 91,111 | $25.71 | $2.3M | By Pivotal bioVenture Partners Fund I, L | Jan 19, 2021 (0d) |
| Jan 13, 2021 | PCVX | ↓ Sell | 97,343 | $26.29 | $2.6M | By Pivotal bioVenture Partners Fund I, L | Jan 13, 2021 (0d) |
| Jan 8, 2021 | PCVX | ↓ Sell | 145,612 | $28.30 | $4.1M | By Pivotal bioVenture Partners Fund I, L | Jan 8, 2021 (0d) |
| Jul 28, 2020 | INZY | ↑ Buy | 187,500 | $16.00 | $3.0M | By Pivotal bioVenture Partners Fund I, L | Jul 28, 2020 (0d) |
| Jun 16, 2020 | PCVX | ↑ Buy | 93,000 | $16.00 | $1.5M | By Pivotal bioVenture Partners Fund I, L | Jun 16, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other EVMN insiders
Open-market trades in the last 12 months
About Robert Lorne Hopfner's insider trades
Robert Lorne Hopfner is a director at Evommune (EVMN). Since Jun 16, 2020, Robert has reported 9 open-market purchases worth $25.2M and 8 sales worth $22.0M on SEC Form 4. In the last 12 months: 1 buy ($17K).
Their filings also include grants and awards (14 filings), conversions (3 filings), other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EVMN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.